The statistics for pancreatic cancer are sobering. With a five-year survival rate of only 9%, incidence of the most common type, pancreatic ductal adenocarcinoma (PDAC), is growing and projected to be the second cause of cancer deaths by 2030. Surgery remains the most effective treatment, yet for 70-80% of patients, surgery is not a viable option. Understanding pancreatic cancer at the cellular and subcellular level is essential for developing therapies that can buy patients more time.
 

To know more about this research:

Digest

Scientific Article

One of the hallmarks of multiple myeloma (MM), a cancer of the bone marrow and one of the most frequent haematological cancers worldwide, is the disruption of the patients’ immune system, which allows the cancer to progress. Now, a study performed by Cristina João, who leads the Myeloma and Lymphoma Research Group at the Champalimaud Centre for the Unknown, and her colleagues, shows how so-called extracellular vesicles (EV’s) released by multiple myeloma cells can drive the disruption of the immune system.

Zoom-In on Champalimaud: Ana Saraiva Ayash

It is with great enthusiasm that we invite you to register for the second hybrid edition of CRSy, to be held at the Champalimaud Centre for the Unknown (CCU), in a stunning setting on the waterfront in Lisbon, Portugal, from October 19–21.

To know more about this research:

Digest

Scientific Article